TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $160

Benzinga · 10/21/2024 17:15
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $157 to $160.